Gender differences in immune reconstitution: A multicentric cohort analysis in sub-saharan africa

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Maman, David ^a,b,d,e,f   Pujades Rodriguez, Mar ^a   Subtil, Fabien ^b,d,e,f   Pinoges, Loretxu ^a   McGuire, Megan ^a   Ecochard, Rene ^b,d,e,f   Etard, Jean François ^a,c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ DE MONTPELLIER   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; TREATMENT DURATION; AFRICA SOUTH OF THE SAHARA; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; SEXUAL DEVELOPMENT; TIME;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SEX CHARACTERISTICS; TIME FACTORS;

EID: 84857170838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031078     Document Type: Article

References (45)

1. World Health Organization (2010) Towards Universal Access; Scaling up priority HIV/AIDS interventionsin the health sector. 2010 Progress Report Geneva World Health Organisation.
2. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-1363.
3. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
4. De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Gueye NF, et al. (2009) Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal. Am J Trop Med Hyg 80: 1047-1053.
5. Garcia F, de Lazzari E, Plana M, Castro P, Mestre G, et al. (2004) Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr 36: 702-713.
6. World Health Organization (2009) Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents.
7. Smith CJ, Sabin CA, Lampe FC, Kinloch-de-Loes S, Gumley H, et al. (2003) The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 17: 963-969.
8. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA, (2000) Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 14: 959-969.
9. Lawn SD, Myer L, Bekker LG, Wood R, (2006) CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 6: 59.
10. Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, et al. (1999) Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 103: 1391-1398.
11. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, et al. (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396: 690-695.
12. Moore RD, Keruly JC, (2007) CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 44: 441-446.
13. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, et al. (2009) Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48: 787-794.
14. Joint United Nations Programme on HIV/AIDS., World Health Organization. (2010) Report on the global HIV/AIDS epidemic Geneva Joint United Nations Programme on HIV/AIDS (UNAIDS): World Health Organization (WHO).
15. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM, (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10: 155-166.
16. Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, et al. (2007) Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health 7: 63.
17. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, et al. (2008) Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 17: 47-55.
18. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R, (2009) The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 14: 722-731.
19. Kigozi IM, Dobkin LM, Martin JN, Geng EH, Muyindike W, et al. (2009) Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr 52: 280-289.
20. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
21. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 (2010) infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
22. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A, (2008) Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 22: 1305-1312.
23. Rabe-Hesketh S, Skrondal A, (2008) Multilevel and longitudinal modeling using Stata College Station, Texas, USA Stata Press.
24. Laird NM, Ware JH, (1982) Random-effects models for longitudinal data. Biometrics 38: 963-974.
25. Casella G, Berger RL, (2002) Statistical Inference.
26. Giordano TP, Wright JA, Hasan MQ, White AC Jr, Graviss EA, et al. (2003) Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 37: 433-437.
27. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, et al. (2003) Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17: 1907-1915.
28. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, et al. (2007) Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 60: 724-732.
29. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
30. Boyer S, Eboko F, Camara M, Abe C, Nguini ME, et al. (2010) Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS 24 (Suppl 1): S5-15.
31. Dou Z, Xu J, Jiao JH, Ma Y, Durako S, et al. (2011) Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008. PLoS One 6: e22707.
32. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, et al. (2008) Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 22: 2291-2302.
33. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, et al. (2011) Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS 25: 1189-1197.
34. Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, et al. (2010) Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 376: 340-345.
35. Bila B, Egrot M, (2009) Gender asymmetry in healthcare-facility attendance of people living with HIV/AIDS in Burkina Faso. Soc Sci Med 69: 854-861.
36. Ekouevi DK, Coffie PA, Chaix ML, Tonwe-Gold B, Amani-Bosse C, et al. (2010) Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Cote d'Ivoire. J Int AIDS Soc 13: 28.
37. Olsen NJ, Kovacs WJ, (2011) Evidence that androgens modulate human thymic T cell output. J Investig Med 59: 32-35.
38. Falster K, Petoumenos K, Chuah J, Mijch A, Mulhall B, et al. (2009) Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. J Acquir Immune Defic Syndr 50: 307-313.
39. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, et al. (2010) Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363: 257-265.
40. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, et al. (2008) CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 22: 841-848.
41. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. (2008) Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197: 1133-1144.
42. The HIV-CAUSAL Collaboration (2010) The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24: 123-137.
43. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, et al. (2003) Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 4: 255-262.
44. Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, et al. (2001) Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 15: 1749-1756.
45. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, et al. (1998) Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 4: 208-214.